文献速递炎症性肠病消化内镜

术后克罗恩病的综合管理进展

Advances in the Comprehensive Management of Postoperative Crohn's Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-04-02

术后克罗恩病患者病情较重、症状混杂且症状缓解对排除肠道炎症敏感性差,管理困难。本文综述了新型无创检测同时排除症状其他原因和评估炎症、内镜监测时机、短肠综合征筛查及术后预防性生物制剂选择等综合管理进展,指出需更多研究评估疗效。

要点

  • 术后克罗恩病症状缓解不能可靠排除肠道炎症,需内镜评估。
  • 术后6个月内应行内镜评估,后续可每1-2年结肠镜监测迟发复发。
  • 术前生物制剂失败者术后预防性生物制剂是审慎的,但选择何种药物缺乏高质量数据。

核心结论

  • 术后克罗恩病管理需综合无创检测、内镜监测和个体化生物制剂选择,但疗效数据仍匮乏。

主要发现

  • 症状缓解对排除术后肠道炎症敏感性差,且该人群生物制剂疗效数据缺乏。
  • 新型无创检测可同时排除症状其他原因(血清C4、粪便脂肪、小肠细菌过度生长呼气试验)并评估炎症(粪钙卫蛋白、内镜下愈合指数)。
  • 多次肠切除患者应筛查短肠综合征。

关键数值与推荐

  • 术后6个月内应行内镜检查,后续可考虑每1-2年结肠镜监测以发现迟发复发。
  • 术前生物制剂失败者术后预防性生物制剂是审慎的,但无高质量数据指导药物选择。
  • 对药物浓度充足仍失败者,选择替代作用机制的生物制剂是合理的;对既往不耐受者选择不同药物是合理的。

临床怎么用

  • 术后患者不应仅凭症状缓解判断炎症控制,应结合无创检测和内镜评估。
  • 术后6个月内安排内镜评估,后续根据风险每1-2年结肠镜监测。
  • 多次肠切除者筛查短肠综合征;术前生物制剂失败者考虑术后预防性生物制剂并个体化选药。

局限性

  • 术后克罗恩病人群生物制剂疗效数据缺乏。
  • 尚无高质量数据指导术后预防性生物制剂的具体选择。
  • 需要显著更多研究评估该背景下治疗的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with postoperative Crohn's disease are difficult to manage because of their risk of experiencing a more severe course, multiple symptom confounders, and poor sensitivity of symptomatic remission to rule out intestinal inflammation. In this group, data are lacking on biologic therapeutic efficacy, and recommendations are lacking for those with multiple medication failures. Novel noninvasive testing can simultaneously exclude alternate causes of symptoms (serum C4, fecal fat, small intestinal bowel overgrowth breath testing) and assess intestinal inflammation (fecal calprotectin, endoscopic healing index). In addition, endoscopy-based disease activity assessment and management are required. Endoscopy should be performed within 6 months of surgery, and aggressive disease activity monitoring can be considered with colonoscopy every 1-2 years subsequently to ensure late recurrence is detected. Patients with multiple resections should be screened for short bowel syndrome. Predictive biomarkers are needed to guide medication selection in this high-risk population. Postoperative prophylactic biologic therapy is prudent for patients with preoperative biologic failure. However, there are no high-quality data to guide which agent should be selected. Selecting biologics with an alternative mechanism of action in those who had failed a biologic with adequate drug concentrations and selection of different agents in those with previous intolerance are reasonable. Significantly more study is required to assess the efficacy of therapies in this setting.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Battat R, Sandborn WJ. Advances in the Comprehensive Management of Postoperative Crohn's Disease. Clin Gastroenterol Hepatol. 2021. PMID: 33819666. doi:10.1016/j.cgh.2021.03.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。